Roche Innovation Center Zurich is Roche Pharma Research and Early Development’s (pRED) Center of Excellence for Cancer Immunotherapy. One major focus is the development of engineered antibodies that address unmet clinical needs. Roche Innovation Center Zurich is one of Roche’s antibody engineering powerhouses.
Glycart Biotechnology AG was initially established in September 2000 as a spin-off of the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland. In the summer of 2005, it was acquired by the Roche Group and integrated in Roche Pharma Research and Early Development (pRED).
The state of the art research complex based in Schlieren, Switzerland, is now an integral part of Roche Pharma Research and Early Development. Roche Innovation Center Zurich is one of seven Roche Pharma Research and Early Development Innovation Centers. It boasts a multinational team of some 185 employees – many of whom are research scientists – with a dynamic, thriving biotech culture. Roche Innovation Center Zurich is headed by Dr Pablo Umaña and comprises of research teams in diverse fields including cancer immunotherapy discovery, pharmacology, molecular biology, cell and protein engineering, process biochemistry, cell biological assays, and histology. The teams belong to the oncology DTA Discovery, Early Development Oncology and global functions including Large Molecule Research, Pharmaceutical Sciences, Data & Analytics, and Operations.
Roche Innovation Center Zurich focuses on product development – from scientific concepts and validation to the corresponding studies. Today the compounds studied and developed are boosting Roche’s significant commitment towards offering improved cancer medicines.